Hydrogel material for retroperitoneal tumor operation wound repair and recurrence prevention
The hydrogel formed by combining materials such as thiolated gelatin and oxidized sodium alginate has solved the problems of difficult wound healing and recurrence after retroperitoneal tumor resection, and has achieved rapid hemostasis, repair and continuous anti-tumor treatment.
Patent Information
- Application Number
- CN202511086058.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-08-05
- Publication Date
- 2025-11-04
Smart Images
Figure CN120884528A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The application belongs to the technical field of biological materials, and particularly relates to a hydrogel material for repairing and preventing recurrence of a retroperitoneal tumor surgical wound. BACKGROUND
[0002] Two clinical problems are faced after retroperitoneal tumor resection: on the one hand, due to the fact that tumors often involve large blood vessels and nerves, the complex wound surface formed after resection has problems such as special anatomical position and large tissue exposure area, resulting in difficult wound healing; on the other hand, the residual microtumor cells after surgery are prone to local recurrence, and the recurrence rate is as high as 60% to 70%. Existing materials have significant limitations: traditional hemostatic materials, such as absorbable gelatin sponge, only have mechanical hemostatic function and lack anti-tumor activity; local chemotherapy drug delivery systems are prone to displacement and loss due to insufficient adhesion; commercially available anti-adhesion membranes, such as polylactic acid membranes, are difficult to fit irregular surgical wounds due to physical rigidity, and cannot provide continuous and effective treatment protection for complex anatomical interfaces.
[0003] Therefore, there is currently a lack of a functional material that can well meet the continuous treatment needs of the wound surface after retroperitoneal tumor resection, and there is an urgent need to develop a new composite material that has immediate sealing, long-term anti-tumor, and precise fitting. SUMMARY
[0004] In order to overcome the shortcomings of the prior art, the purpose of the present application is to provide a hydrogel material for repairing and preventing recurrence of a retroperitoneal tumor surgical wound, so as to solve the problem that functional materials cannot well meet the continuous treatment needs of the wound surface after retroperitoneal tumor resection.
[0005] To achieve the above-mentioned purpose, the present application provides the following technical solutions:
[0006] A hydrogel material for repairing and preventing recurrence of a retroperitoneal tumor surgical wound, comprising a matrix phase, a functional phase, an auxiliary phase and a solvent, the matrix phase comprising mercaptized gelatin, oxidized sodium alginate, polyvinyl alcohol and carboxymethyl chitosan, the functional phase comprising drug-loaded nanoparticles and recombinant human collagen, and the auxiliary phase comprising calcium chloride, glutaraldehyde, graphene oxide and vitamin E succinate.
[0007] Preferably, the drug-loaded nanoparticles are composed of a hollow mesoporous silica core and a temperature-sensitive polymeric shell, the core loaded with doxorubicin, cyclophosphamide, resveratrol, alcohol elemanol and paclitaxel, and the shell being N-isopropyl acrylamide.
[0008] Preferably, the mass ratio of doxorubicin, cyclophosphamide, resveratrol, alcohol elemanol and paclitaxel is 8:8:6:3:6.
[0009] Preferably, the mass ratio of the mercapto gelatin, oxidized sodium alginate, polyvinyl alcohol and carboxymethyl chitosan is 8-12:3-5:5-10:1-2.
[0010] Preferably, the mass ratio of the drug-loaded nanoparticles and the recombinant human collagen is 5-8:2-4.
[0011] Preferably, the mass ratio of the calcium chloride, glutaraldehyde, graphene oxide and vitamin E succinate is 0.5-1:0.5-1.5:0.1-0.5:0.1-0.3.
[0012] Preferably, the drug-loaded nanoparticles are prepared by the following steps:
[0013] The hollow mesoporous silica inner core is prepared by treating the CTAB template and the TEOS precursor by the sol-gel method;
[0014] The doxorubicin, cyclophosphamide, resveratrol, alcohol elemanen and paclitaxel are introduced into the hollow mesoporous silica inner core by vacuum adsorption, and the pH value is adjusted to 7-8 by PBS;
[0015] The nanoparticles, NIPAM monomers and CuBr catalyst are mixed to coat the hollow mesoporous silica inner core to form an outer shell, and the drug-loaded nanoparticles are obtained after being frozen at-80℃ for 48h.
[0016] Preferably, the concentration of the doxorubicin is 2mg / mL, the concentration of the cyclophosphamide is 2mg / mL, the concentration of the resveratrol RES is 1mg / mL, the concentration of the alcohol elemanen is 0.5mg / mL, and the concentration of the paclitaxel is 1mg / mL.
[0017] Preferably, the in-situ synthesis process of the hydrogel comprises:
[0018] 10% mercapto gelatin, 8% polyvinyl alcohol, 4% recombinant human collagen, 0.5% glutaraldehyde, 0.5% graphene oxide and 0.8% vitamin E succinate are dissolved in deionized water at 4℃ to prepare liquid phase A;
[0019] 4% oxidized sodium alginate, 2% carboxymethyl chitosan, 6% drug-loaded nanoparticles and 0.8% CaCl2 are dissolved in PBS to prepare liquid phase B;
[0020] Liquid phases A and B are injected into the wound surface in equal volume, and the gelation is completed at 37℃ for 90s.
[0021] Compared with the prior art, the present application has the following beneficial effects:
[0022] The present application is by setting the matrix phase, functional phase, auxiliary phase and solvent composition of the hydrogel material, sulfhydrylated gelatin and oxidized sodium alginate can be quickly completed gelation under the action of calcium chloride at body temperature environment, form the first gel body, then in the first gel body, polyvinyl alcohol and carboxymethyl chitosan form the second gel body under the action of glutaraldehyde and graphene oxide, prolong the existence time of the gel body, form the sustained protection of postoperative wound, realize the rapid hemostasis of tumor wound and promote the rapid repair of postoperative large wound, the hydrogel can effectively isolate the retroperitoneal organs, reduce postoperative adhesion, the gel body can be connected on the surface of the wound tissue to promote the migration of fibroblasts, and with the decomposition of the gel body, the drug-loaded nanoparticles in the gel body are continuously released, and act on the postoperative wound to continuously inhibit tumor cells and avoid tumor cell regeneration. BRIEF DESCRIPTION OF DRAWINGS
[0023] Figure 1 A hydrogel material composition for retroperitoneal tumor surgical wound repair and prevention of recurrence is disclosed.
[0024] Figure 2 A hydrogel for retroperitoneal tumor surgical wound repair and prevention of recurrence is disclosed. DETAILED DESCRIPTION
[0025] The technical solutions in the embodiments of the present application will be described clearly and completely in combination with the drawings in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, rather than all the embodiments. Based on the embodiments in the present application, all other embodiments obtained by those skilled in the art without creative labor fall within the scope of protection of the present application.
[0026] Embodiment one:
[0027] Please refer to Figure 1 - Figure 2 Please refer to Figure 1 - Figure 2 As shown in the figure, a hydrogel material for retroperitoneal tumor surgical wound repair and prevention of recurrence includes a matrix phase, a functional phase, an auxiliary phase and a solvent, the matrix phase includes sulfhydrylated gelatin, oxidized sodium alginate, polyvinyl alcohol and carboxymethyl chitosan, the functional phase includes drug-loaded nanoparticles and recombinant human collagen, and the auxiliary phase includes calcium chloride, glutaraldehyde, graphene oxide and vitamin E succinate.
[0028] As can be seen from the above, by setting the matrix phase, functional phase, auxiliary phase and solvent to form the hydrogel material, the mercapto gelatin and oxidized sodium alginate can rapidly complete gelation at body temperature under the action of calcium chloride to form a first gel body, and then in the first gel body, polyvinyl alcohol and carboxymethyl chitosan form a second gel body under the action of glutaraldehyde and graphene oxide, the existence time of the gel body is prolonged, the continuous protection of the postoperative wound is formed, the rapid hemostasis of the tumor wound is realized, the rapid repair of the large postoperative wound is promoted, the hydrogel can effectively isolate the retroperitoneal organs and reduce postoperative adhesion, the gel body can be connected to the surface of the wound tissue to provide adhesion sites for RGD, promote fibroblast migration, and calcium ions are continuously released to activate tissue factor XIII, promote postoperative wound repair, and at the same time, with the decomposition of the gel body, the drug-loaded nanoparticles in the gel body are continuously released to continuously inhibit tumor cells on the postoperative wound, avoiding tumor cell regeneration.
[0029] Recombinant human collagen can promote fibroblast migration, and vitamin E succinate can provide antioxidant and anti-fibrosis effects.
[0030] The drug-loaded nanoparticles are composed of a hollow mesoporous silica inner core and a temperature-sensitive polymeric shell, the inner core is loaded with doxorubicin, cyclophosphamide, resveratrol, alcohol elemanol and paclitaxel, and the shell is N-isopropyl acrylamide, the shell material has hydrophilic amide groups and hydrophobic isopropyl groups, and its homopolymer and copolymer exhibit temperature response characteristics and are widely used in the preparation of temperature-sensitive hydrogels, drug controlled release systems and intelligent materials.
[0031] In the treatment of tumor surgery, doxorubicin, as a classic chemotherapy drug, mainly inserts into DNA base pairs and inhibits the activity of topoisomerase II, interferes with the synthesis of genetic material of tumor cells, and thus plays a strong killing effect. It is suitable for intraoperative local slow-release administration, which can effectively remove residual microtumor cells on the surgical wound, especially for soft tissue sarcoma and the like, but attention should be paid to control the dose to avoid the vascular toxicity effect on the surrounding normal tissues. Resveratrol plays a role in tumor surgery due to its unique epigenetic regulation function, reduces the invasiveness of tumor cells by inhibiting key signaling pathways such as STAT3 / NF-κB, and regulates the activity of immune cells in the tumor microenvironment to enhance the body's anti-tumor immune response. Its antioxidant properties can also reduce oxidative stress damage caused by surgical trauma, and it is suitable for low-dose slow-release form for postoperative recurrence prevention treatment.
[0032] Cyclophosphamide, when used in combination with doxorubicin, is a classic chemotherapy regimen for treating various cancers. Their synergistic effect is primarily manifested in their enhanced efficacy: doxorubicin interferes with DNA replication and RNA synthesis by intercalating into DNA and inhibiting topoisomerase II, while simultaneously generating reactive oxygen species to damage tumor cells; cyclophosphamide, after being metabolized in vivo, forms an active product that cross-links with DNA, directly disrupting DNA structure and preventing cell division. These two drugs attack tumor cells through different mechanisms; when used together, they simultaneously damage tumor cells' DNA and division capacity via multiple pathways, significantly enhancing the killing effect. Furthermore, cyclophosphamide may inhibit certain DNA repair pathways, making the DNA damage caused by doxorubicin more difficult to repair, further improving efficacy. This combination is widely used in adjuvant and neoadjuvant chemotherapy for breast cancer, as well as for treating some other malignant tumors, typically producing higher response rates than single-agent use.
[0033] Elecithin, a naturally derived antitumor drug, inhibits tumor cell mitosis by interfering with microtubule function and plays a crucial role in reversing multidrug resistance in tumors. In surgical applications, this drug is particularly suitable for treating thoracic and peritoneal metastases via serous cavity perfusion. Its lipid solubility allows it to combine with fat emulsions to increase local drug concentration, and it exhibits lower neurotoxicity compared to paclitaxel-based drugs, providing an advantage for combination therapy. Paclitaxel, on the other hand, exerts its antitumor effect by stabilizing microtubule structure and preventing normal depolymerization. This unique mechanism makes it an important option for intraoperative local treatment of tumors such as breast cancer and ovarian cancer, especially when combined with hyperthermic perfusion therapy, significantly improving the clearance of peritoneal disseminated lesions. However, attention should be paid to potential adverse reactions such as peripheral neuropathy.
[0034] The combination of doxorubicin and resveratrol can achieve a dual attack on DNA damage and epigenetic regulation, while the combination of paclitaxel and elemol can synergistically act on the microtubule system through different pathways. The four-drug combination can cover all stages of the cell cycle and reshape the tumor microenvironment. In particular, when hydrogels are used as drug carriers, the four drugs can be released slowly, which can prolong the good therapeutic effect of the drugs while reducing toxic side effects.
[0035] The steps for fabricating the drug-loaded nanoparticles are as follows:
[0036] Hollow mesoporous silica cores were prepared by treating CTAB templates and TEOS precursors using the sol-gel method.
[0037] Doxorubicin, cyclophosphamide, resveratrol, limonene and paclitaxel were introduced into the hollow mesoporous silica core by vacuum adsorption, and the pH was adjusted to 7-8 using PBS;
[0038] The nanoparticles, NIPAM monomers and CuBr catalyst were mixed and coated onto the surface of a hollow mesoporous silica core to form a shell. After freezing at -80℃ for 48 hours, drug-loaded nanoparticles were obtained.
[0039] The concentration of doxorubicin is 2 mg / mL, the concentration of cyclophosphamide is 2 mg / mL, the concentration of resveratrol (RES) is 1 mg / mL, the concentration of elemol is 0.5 mg / mL, and the concentration of paclitaxel is 1 mg / mL.
[0040] The in-situ synthesis process of the hydrogel includes:
[0041] Liquid phase A was prepared by dissolving 10% thiolated gelatin, 8% polyvinyl alcohol, 4% recombinant human collagen, 0.5% glutaraldehyde, 0.5% graphene oxide and 0.8% vitamin E succinate in deionized water at 4°C.
[0042] Liquid phase B was prepared by dissolving 4% sodium alginate, 2% carboxymethyl chitosan, 6% drug-loaded nanoparticles and 0.8% CaCl2 in PBS.
[0043] Equal volumes of liquid phase A and liquid phase B were injected into the wound, and gelation was completed in 90 seconds at 37°C.
[0044] Example 2:
[0045] Please see Figure 1 - Figure 2 As shown, a hydrogel material for repairing surgical wounds and preventing recurrence of retroperitoneal tumors includes a matrix phase, a functional phase, an auxiliary phase, and a solvent. The matrix phase includes thiolated gelatin, sodium alginate oxide, polyvinyl alcohol, and carboxymethyl chitosan. The functional phase includes drug-loaded nanoparticles and recombinant human collagen. The auxiliary phase includes calcium chloride, glutaraldehyde, graphene oxide, and vitamin E succinate.
[0046] As shown above, by setting up a hydrogel material composed of a matrix phase, a functional phase, an auxiliary phase, and a solvent, thiolated gelatin and sodium alginate oxide can rapidly gel at body temperature under the action of calcium chloride to form a first gel body. Then, inside the first gel body, polyvinyl alcohol and carboxymethyl chitosan form a second gel body under the action of glutaraldehyde and graphene oxide, prolonging the existence time of the gel body and forming a continuous protection for the postoperative wound. This achieves rapid hemostasis of the tumor wound while promoting rapid repair of large postoperative wounds. The hydrogel can effectively isolate retroperitoneal organs and reduce postoperative adhesions. The gel body can connect to the surface of wound tissue, providing adhesion sites for RGD, promoting fibroblast migration, and continuously releasing calcium ions to activate coagulation factor XIII in the tissue, promoting postoperative wound repair. At the same time, as the gel body decomposes, drug-loaded nanoparticles inside the gel body are continuously released, acting on the postoperative wound surface to continuously inhibit tumor cells and prevent tumor cell regeneration.
[0047] Recombinant human collagen can promote fibroblast migration, while vitamin E succinate can provide antioxidant and anti-fibrotic effects.
[0048] The drug-loaded nanoparticles consist of a hollow mesoporous silica core and a temperature-sensitive polymeric shell. The core is loaded with doxorubicin, cyclophosphamide, resveratrol, elemol, and paclitaxel, while the shell is N-isopropylacrylamide. The shell material has both hydrophilic amide groups and hydrophobic isopropyl groups. Its homopolymers and copolymers exhibit temperature-responsive characteristics and are widely used in the preparation of temperature-sensitive hydrogels, drug controlled-release systems, and smart materials.
[0049] In tumor surgery, doxorubicin, a classic chemotherapeutic drug, exerts its potent killing effect primarily by interfering with the synthesis of genetic material in tumor cells through DNA base pair insertion and inhibition of topoisomerase II activity. It is suitable for intraoperative local sustained-release administration, effectively clearing residual microtumor cells from the surgical wound, particularly effective against soft tissue sarcomas. However, dosage control is crucial to avoid vascular toxicity to surrounding normal tissues. Resveratrol, on the other hand, plays a role in tumor surgery due to its unique epigenetic regulatory function. It reduces tumor cell invasiveness by inhibiting key signaling pathways such as STAT3 / NF-κB, while simultaneously regulating the activity of immune cells in the tumor microenvironment and enhancing the body's anti-tumor immune response. Its antioxidant properties also alleviate oxidative stress damage caused by surgical trauma, making it suitable for postoperative recurrence prevention treatment in low-dose sustained-release form.
[0050] Cyclophosphamide, when used in combination with doxorubicin, is a classic chemotherapy regimen for treating various cancers. Their synergistic effect is primarily manifested in their enhanced efficacy: doxorubicin interferes with DNA replication and RNA synthesis by intercalating into DNA and inhibiting topoisomerase II, while simultaneously generating reactive oxygen species to damage tumor cells; cyclophosphamide, after being metabolized in vivo, forms an active product that cross-links with DNA, directly disrupting DNA structure and preventing cell division. These two drugs attack tumor cells through different mechanisms; when used together, they simultaneously damage tumor cells' DNA and division capacity via multiple pathways, significantly enhancing the killing effect. Furthermore, cyclophosphamide may inhibit certain DNA repair pathways, making the DNA damage caused by doxorubicin more difficult to repair, further improving efficacy. This combination is widely used in adjuvant and neoadjuvant chemotherapy for breast cancer, as well as for treating some other malignant tumors, typically producing higher response rates than single-agent use.
[0051] Elecithin, a naturally derived antitumor drug, inhibits tumor cell mitosis by interfering with microtubule function and plays a crucial role in reversing multidrug resistance in tumors. In surgical applications, this drug is particularly suitable for treating thoracic and peritoneal metastases via serous cavity perfusion. Its lipid solubility allows it to combine with fat emulsions to increase local drug concentration, and it exhibits lower neurotoxicity compared to paclitaxel-based drugs, providing an advantage for combination therapy. Paclitaxel, on the other hand, exerts its antitumor effect by stabilizing microtubule structure and preventing normal depolymerization. This unique mechanism makes it an important option for intraoperative local treatment of tumors such as breast cancer and ovarian cancer, especially when combined with hyperthermic perfusion therapy, significantly improving the clearance of peritoneal disseminated lesions. However, attention should be paid to potential adverse reactions such as peripheral neuropathy.
[0052] The combination of doxorubicin and resveratrol can achieve a dual attack on DNA damage and epigenetic regulation, while the combination of paclitaxel and elemol can synergistically act on the microtubule system through different pathways. The four-drug combination can cover all stages of the cell cycle and reshape the tumor microenvironment. In particular, when hydrogels are used as drug carriers, the four drugs can be released slowly, which can prolong the good therapeutic effect of the drugs while reducing toxic side effects.
[0053] The mass ratio of doxorubicin, cyclophosphamide, resveratrol, elemol, and paclitaxel is 8:8:6:3:6; the mass ratio of thiolated gelatin, sodium alginate oxide, polyvinyl alcohol, and carboxymethyl chitosan is 8-12:3-5:5-10:1-2; the mass ratio of drug-loaded nanoparticles and recombinant human collagen is 5-8:2-4; and the mass ratio of calcium chloride, glutaraldehyde, graphene oxide, and vitamin E succinate is 0.5-1:0.5-1.5:0.1-0.5:0.1-0.3.
[0054] The steps for fabricating the drug-loaded nanoparticles are as follows:
[0055] Hollow mesoporous silica cores were prepared by treating CTAB templates and TEOS precursors using the sol-gel method.
[0056] Doxorubicin, cyclophosphamide, resveratrol, limonene and paclitaxel were introduced into the hollow mesoporous silica core by vacuum adsorption, and the pH was adjusted to 7-8 using PBS;
[0057] The nanoparticles, NIPAM monomers and CuBr catalyst were mixed and coated onto the surface of a hollow mesoporous silica core to form a shell. After freezing at -80℃ for 48 hours, drug-loaded nanoparticles were obtained.
[0058] The concentration of doxorubicin is 2 mg / mL, the concentration of cyclophosphamide is 2 mg / mL, the concentration of resveratrol (RES) is 1 mg / mL, the concentration of elemol is 0.5 mg / mL, and the concentration of paclitaxel is 1 mg / mL.
[0059] The in-situ synthesis process of the hydrogel includes:
[0060] Liquid phase A was prepared by dissolving 10% thiolated gelatin, 8% polyvinyl alcohol, 4% recombinant human collagen, 0.5% glutaraldehyde, 0.5% graphene oxide and 0.8% vitamin E succinate in deionized water at 4°C.
[0061] Liquid phase B was prepared by dissolving 4% sodium alginate, 2% carboxymethyl chitosan, 6% drug-loaded nanoparticles and 0.8% CaCl2 in PBS.
[0062] Equal volumes of liquid phase A and liquid phase B were injected into the wound, and gelation was completed in 90 seconds at 37°C.
[0063] In the description of this invention, the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of indicated technical features. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. "A plurality of" means two or more, unless otherwise explicitly specified.
[0064] In the description of this specification, the references to terms such as "one embodiment," "some embodiments," "example," "specific example," or "some examples," etc., indicate that a specific feature, structure, material, or characteristic described in connection with that embodiment or example is included in at least one embodiment or example of the present invention. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. Moreover, without contradiction, those skilled in the art can combine and integrate the different embodiments or examples described in this specification, as well as the features of different embodiments or examples.
[0065] The accompanying drawings of the embodiments disclosed in this invention only involve structures relevant to the embodiments disclosed in this invention. Other structures can be referred to with common designs. Unless otherwise specified, the same embodiment and different embodiments of this invention can be combined with each other.
Claims
1. A hydrogel material for repairing surgical wounds and preventing recurrence of retroperitoneal tumors, characterized in that, It includes a matrix phase, a functional phase, an auxiliary phase, and a solvent. The matrix phase includes thiolated gelatin, sodium alginate oxide, polyvinyl alcohol, and carboxymethyl chitosan. The functional phase includes drug-loaded nanoparticles and recombinant human collagen. The auxiliary phase includes calcium chloride, glutaraldehyde, graphene oxide, and vitamin E succinate.
2. The hydrogel material for repairing surgical wounds and preventing recurrence of retroperitoneal tumors according to claim 1, characterized in that: The drug-loaded nanoparticles consist of a hollow mesoporous silica core and a temperature-sensitive polymeric shell. The core is loaded with doxorubicin, cyclophosphamide, resveratrol, elemol, and paclitaxel, and the shell is N-isopropylacrylamide.
3. The hydrogel material for repairing surgical wounds and preventing recurrence of retroperitoneal tumors according to claim 2, characterized in that: The mass ratio of doxorubicin, cyclophosphamide, resveratrol, elemol, and paclitaxel is 8:8:6:3:
6.
4. The hydrogel material for repairing surgical wounds and preventing recurrence of retroperitoneal tumors according to claim 1, characterized in that: The mass ratio of the thiolated gelatin, sodium alginate oxide, polyvinyl alcohol, and carboxymethyl chitosan is 8–12:3–5:5–10:1–2.
5. The hydrogel material for repairing surgical wounds and preventing recurrence of retroperitoneal tumors according to claim 1, characterized in that: The mass ratio of the drug-loaded nanoparticles to recombinant human collagen is 5-8:2-4.
6. The hydrogel material for repairing surgical wounds and preventing recurrence of retroperitoneal tumors according to claim 1, characterized in that: The mass ratio of calcium chloride, glutaraldehyde, graphene oxide and vitamin E succinate is 0.5-1:0.5-1.5:0.1-0.5:0.1-0.
3.
7. The hydrogel material for repairing surgical wounds and preventing recurrence of retroperitoneal tumors according to claim 2, characterized in that: The steps for fabricating the drug-loaded nanoparticles are as follows: Hollow mesoporous silica cores were prepared by treating CTAB templates and TEOS precursors using the sol-gel method. Doxorubicin, cyclophosphamide, resveratrol, limonene and paclitaxel were introduced into the hollow mesoporous silica core by vacuum adsorption, and the pH was adjusted to 7-8 using PBS; The nanoparticles, NIPAM monomers and CuBr catalyst were mixed and coated onto the surface of a hollow mesoporous silica core to form a shell. After freezing at -80℃ for 48 hours, drug-loaded nanoparticles were obtained.
8. The hydrogel material for repairing surgical wounds and preventing recurrence of retroperitoneal tumors according to claim 7, characterized in that: The concentration of doxorubicin is 2 mg / mL, the concentration of cyclophosphamide is 2 mg / mL, the concentration of resveratrol (RES) is 1 mg / mL, the concentration of elemol is 0.5 mg / mL, and the concentration of paclitaxel is 1 mg / mL.
9. The hydrogel material for repairing surgical wounds and preventing recurrence of retroperitoneal tumors according to claim 1, characterized in that: The in-situ synthesis process of the hydrogel includes: Liquid phase A was prepared by dissolving 10% thiolated gelatin, 8% polyvinyl alcohol, 4% recombinant human collagen, 0.5% glutaraldehyde, 0.5% graphene oxide and 0.8% vitamin E succinate in deionized water at 4°C. Liquid phase B was prepared by dissolving 4% sodium alginate, 2% carboxymethyl chitosan, 6% drug-loaded nanoparticles and 0.8% CaCl2 in PBS. Equal volumes of liquid phase A and liquid phase B were injected into the wound, and gelation was completed in 90 seconds at 37°C.